2024-10-09 - Analysis Report
## Regeneron Pharmaceuticals Inc (REGN) Stock Analysis

This report provides a comprehensive analysis of Regeneron Pharmaceuticals Inc (REGN) based on the provided data.

**1. Performance Comparison with S&P 500 (VOO)**

Regeneron Pharmaceuticals Inc (REGN) is a leading biotechnology company developing and commercializing life-changing medicines for serious diseases. 

* **Cumulative Return:** REGN has a cumulative return of 92.97%, while the S&P 500 (VOO) has a cumulative return of 133.14%.
* **Performance Gap:** REGN lags behind VOO by -40.17%, with a relative divergence of 35.43%. This indicates that REGN has been underperforming compared to the S&P 500, though it is currently at a higher point in its past performance range.

**2. Recent Price Action**

* **Closing Price:** $1012.82
* **5-day Moving Average:** $1033.17
* **20-day Moving Average:** $1094.86
* **60-day Moving Average:** $1115.43

The current price is below all three moving averages, suggesting a short-term downward trend.

**3. Technical Indicators**

* **RSI:** 22.12, indicating the stock is in oversold territory.
* **PPO:** -0.9, suggesting a bearish trend.
* **Delta_Previous_Relative_Divergence:** -27.97, indicates a recent short-term downward trend.
* **Expected_Return:** 0.0%, indicating no significant expected return over the next 5 years compared to the S&P 500.

**4. Recent Earnings & Outlook**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-01 | 13.25 | $3.55 B |
| 2024-05-02 | 6.7 | $3.15 B |
| 2023-11-02 | 9.48 | $3.36 B |
| 2023-08-03 | 9.05 | $3.16 B |
| 2024-08-01 | 9.05 | $3.16 B |

The most recent earnings for Q2 2024 surpassed analyst expectations. This positive earnings beat suggests a potential rebound for the stock. However, it's important to consider that the overall market sentiment is still cautious.

**5. News & Recent Issues**

* **Recent Market Outlook:** REGN's stock has experienced a downward trend due to concerns over the company's growth prospects in the face of increased competition and potential regulatory challenges.
* **Analyst Opinions:** Analyst opinions on REGN remain mixed. While some analysts remain optimistic, others are cautious, citing concerns over pricing pressures and competition. 
* **Performance Highlights:** REGN's recent performance has been impacted by the challenging market environment and the regulatory scrutiny of its blockbuster drug Eylea. 

**6. Comprehensive Analysis**

Overall, REGN is currently facing a challenging period. Despite its recent strong earnings report, the stock is facing headwinds due to market concerns over its growth prospects and potential regulatory hurdles. Technical indicators suggest that the stock is currently in oversold territory, indicating a potential rebound. However, the lack of a significant expected return and the mixed analyst opinions warrant caution.

**7. Conclusion**

While REGN's recent earnings report was positive, its overall market sentiment remains cautious. The stock is facing challenges due to competition and regulatory uncertainties. While the oversold condition suggests potential for a rebound, the limited expected return and mixed analyst opinions require investors to proceed with caution. 
